Revvity (RVTY) Jumps After Raising 2026 EPS Outlook

Revvity shares rose about 7% premarket on Nov. 3 after the life-sciences group lifted its 2026 adjusted EPS outlook to $5.40-$5.45 on a third-quarter revenue beat.

Lead

What Did Revvity Report for the Third Quarter?

Revvity reported pro forma revenue of $710 million, up 7% organically, which exceeded the company's own mid-single-digit guidance. Adjusted operating margin was 29.4%, about 40 basis points better than management had projected. Free cash flow was $152 million, equal to 99% of adjusted net income, and has topped $450 million year to date.

The Life Sciences segment generated $380 million in revenue, with 9% organic growth. Reagents grew at a high single-digit rate and instruments at a mid-single-digit rate. Bulk orders added roughly 100 basis points to reagent growth. Segment operating margin widened to 13.1% from 11.7% a year earlier.

How Much Did Revvity Raise Its 2026 Guidance?

Revvity raised the low end of its adjusted EPS range by 10 cents, moving it to $5.40-$5.45 from $5.30-$5.40. The new midpoint of $5.425 sits above the $5.35 consensus and implies adjusted EPS growth of about 12% from 2025.

Full-year pro forma revenue is now expected at about $2.86 billion, the top of the prior $2.83-$2.86 billion range, compared with a consensus near $2.85 billion. Pro forma organic growth is projected at about 5%, up from 4%-5%.

The fourth-quarter implied outlook points to revenue of about $755 million, adjusted operating margin slightly above 32%, and adjusted EPS of about $1.60 at the midpoint.

Why Did the Shares React So Strongly?

The shares reacted because the quarter combined a revenue beat, margin upside and a higher earnings floor in a sector where demand has been uneven. Life-sciences tools companies have spent two years contending with soft academic funding, cautious biopharma budgets and weak Chinese demand. Revvity's 9% organic growth in Life Sciences stands out against that backdrop, and the strength in reagents points to recurring consumables demand rather than one-off instrument purchases.

Management also said it is using part of recently received tariff refunds to increase investment across the business. That choice means the EPS raise comes after spending on growth initiatives, not through a pullback. Even with that reinvestment, operating margin improved in both segments.

The size of the move also reflects the gap between results and expectations. The revenue beat of roughly 5% against consensus is large for a mature tools and diagnostics business, and the guidance range tightened upward at the same time.

What Comes Next for Revvity?

The next test is whether the 5% organic growth rate holds through the fourth quarter. The implied Q4 figures call for a higher operating margin than Q3, which depends on cost discipline and continued reagent demand. Bulk orders flattered third-quarter reagent growth, so the comparison will be tougher if those orders do not repeat.

Key variables include biopharma and academic research funding, the pace of immunodiagnostics demand outside China, and the stabilization of Chinese reproductive-health testing. Free cash flow conversion near 100% leaves room for capital returns and bolt-on acquisitions, which have been part of the company's portfolio reshaping.

Market Context

Revvity's move was driven by company-specific results rather than a sector rally. Peers in diagnostics and life-sciences tools tend to trade on read-through from such reports, and a raised guide from a mid-cap name with exposure to both research and clinical testing offers a data point on end-market health heading into year-end.

Outlook

Revvity enters the final quarter with a higher earnings floor, a revenue run rate near $2.86 billion and margins expanding in both segments. The raised guidance shifts the debate from whether growth can hold above 4% to whether the company can deliver the roughly 32% fourth-quarter operating margin it has implied.